The evolution of Magtrace: Breaking down the data behind the world’s most versatile lymphatic tracer

Adopting new technologies can feel like taking a step into the unknown. Fortunately, Magtrace has built a comprehensive clinical data library over the last decade that demonstrates why it offers a unique new approach to axilla management.

Speaking at the Transatlantic Breast Cancer Collaborative meeting, Kandace McGuire MD drew upon data from over 100 studies, featuring 8,000+ patients, to summarise the key studies that show Magtrace to be non-inferior to the “gold standard” for SLNB — as well as provide opportunities to de-escalate surgery through groundbreaking new techniques.

Watch as Dr McGuire discusses: 

  • The wealth of Magtrace data, proving it’s non-inferiority to the ‘gold standard’ for SLNB. 
  • How multiple studies show that reducing the injection volume to 1ml* demonstrates equivalent performance and can minimize temporary skin discoloration. 
  • The MagTotal study demonstrates that Magtrace can be used to great effect alongside Magseed, with a very low re-excision rate of less than 3% and high clinical satisfaction. 
  • Revolutionary techniques such as MagUS (2021), which could offer a minimally invasive axillary mapping technique and has been shown to perform comparatively to baseline axillary ultrasound.

→ Watch more of the key debates from TBCC 2022 here 

*Indication varies between countries. Please check your IFU for injection guidance.